{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:32:59Z","timestamp":1778067179264,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100031478","name":"NextGenerationEU","doi-asserted-by":"publisher","award":["ECS00000041 - VITALITY \u2013 CUP H33C22000430006"],"award-info":[{"award-number":["ECS00000041 - VITALITY \u2013 CUP H33C22000430006"]}],"id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Antimicrob Resist"],"DOI":"10.1038\/s44259-026-00198-4","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:54:42Z","timestamp":1776257682000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Candidozyma auris-infected Galleria mellonella larvae: the effect of the humanized monoclonal antibody Dia-T51 and its synergy with amphotericin B"],"prefix":"10.1038","volume":"4","author":[{"given":"Tania","family":"Vanzolini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Fiori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Magnani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"198_CR1","unstructured":"Nguyen, I. K. Fungal infections: a rising global concern by ISID emerging leader, Afreenish Amir - ISID. https:\/\/isid.org\/fungal-infections-a-rising-global-concern-by-isid-emerging-leader-afreenish-amir\/, https:\/\/isid.org\/fungal-infections-a-rising-global-concern-by-isid-emerging-leader-afreenish-amir\/ (2024)."},{"key":"198_CR2","doi-asserted-by":"publisher","first-page":"e428","DOI":"10.1016\/S1473-3099(23)00692-8","volume":"24","author":"DW Denning","year":"2024","unstructured":"Denning, D. W. Global incidence and mortality of severe fungal disease. Lancet Infect. Dis. 24, e428\u2013e438 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"198_CR3","unstructured":"CDC. Antibiotic-resistant Germs: New Threats. Centers for Disease Control and Prevention https:\/\/www.cdc.gov\/drugresistance\/biggest-threats.html (2021)."},{"key":"198_CR4","unstructured":"WHO Fungal Priority Pathogens List to Guide Research, Development and Public Health Action (World Health Organization, Geneva, 2022)."},{"key":"198_CR5","doi-asserted-by":"publisher","first-page":"e482","DOI":"10.1016\/S2666-5247(23)00114-3","volume":"4","author":"SK Mishra","year":"2023","unstructured":"Mishra, S. K., Yasir, M. & Willcox, M. Candida auris: an emerging antimicrobial-resistant organism with the highest level of concern. Lancet Microbe 4, e482\u2013e483 (2023).","journal-title":"Lancet Microbe"},{"key":"198_CR6","unstructured":"C. D. C. Antifungal Susceptibility Testing for C. auris. Candida auris (C. auris), https:\/\/www.cdc.gov\/candida-auris\/hcp\/laboratories\/antifungal-susceptibility-testing.html (2024)."},{"key":"198_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00253-023-12884-8","volume":"108","author":"T Vanzolini","year":"2024","unstructured":"Vanzolini, T. & Magnani, M. Old and new strategies in therapy and diagnosis against fungal infections. Appl. Microbiol. Biotechnol. 108, 147 (2024).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"198_CR8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3390\/ijms23010545","volume":"23","author":"T Vanzolini","year":"2022","unstructured":"Vanzolini, T., Bruschi, M., Rinaldi, A. C., Magnani, M. & Fraternale, A. Multitalented synthetic antimicrobial peptides and their antibacterial, antifungal and antiviral mechanisms. Int. J. Mol. Sci. 23, 545 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"198_CR9","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1084\/jem.20050749","volume":"202","author":"A Torosantucci","year":"2005","unstructured":"Torosantucci, A. et al. A novel glyco-conjugate vaccine against fungal pathogens. J. Exp. Med. 202, 597\u2013606 (2005).","journal-title":"J. Exp. Med."},{"key":"198_CR10","doi-asserted-by":"publisher","first-page":"e5392","DOI":"10.1371\/journal.pone.0005392","volume":"4","author":"A Torosantucci","year":"2009","unstructured":"Torosantucci, A. et al. Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PloS One 4, e5392 (2009).","journal-title":"PloS One"},{"key":"198_CR11","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1128\/IAI.00278-07","volume":"75","author":"A Rachini","year":"2007","unstructured":"Rachini, A. et al. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect. Immun. 75, 5085\u20135094 (2007).","journal-title":"Infect. Immun."},{"key":"198_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12896-020-00607-0","volume":"20","author":"M Catellani","year":"2020","unstructured":"Catellani, M. et al. Optimised production of an anti-fungal antibody in Solanaceae hairy roots to develop new formulations against Candida albicans. BMC Biotechnol 20, 15 (2020).","journal-title":"BMC Biotechnol"},{"key":"198_CR13","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11046-011-9476-9","volume":"173","author":"RA Bryan","year":"2012","unstructured":"Bryan, R. A. et al. Toward developing a universal treatment for fungal disease using radioimmunotherapy targeting common fungal antigens. Mycopathologia 173, 463\u2013471 (2012).","journal-title":"Mycopathologia"},{"key":"198_CR14","unstructured":"Di Mambro, T., Vanzolini, T. & Magnani, M. Humanised antibodies against pathogenic fungi. Patent WO2022096455A1 (2022)."},{"key":"198_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-98659-5","volume":"11","author":"T Di Mambro","year":"2021","unstructured":"Di Mambro, T. et al. A new humanized antibody is effective against pathogenic fungi in vitro. Sci. Rep. 11, 19500 (2021).","journal-title":"Sci. Rep."},{"key":"198_CR16","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.1039\/D2RA07217C","volume":"13","author":"T Vanzolini","year":"2023","unstructured":"Vanzolini, T., Mambro, T. D., Magnani, M. & Menotta, M. AFM evaluation of a humanized recombinant antibody affecting C. auris cell wall and stability. RSC Adv. 13, 6130\u20136142 (2023).","journal-title":"RSC Adv."},{"key":"198_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/13693780410001731547","volume":"43","author":"J Meletiadis","year":"2005","unstructured":"Meletiadis, J., Verweij, P. E., TeDorsthorst, D. T. A., Meis, J. F. G. M. & Mouton, J. W. Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. Med. Mycol. 43, 133\u2013152 (2005).","journal-title":"Med. Mycol."},{"key":"198_CR18","doi-asserted-by":"publisher","first-page":"a019653","DOI":"10.1101\/cshperspect.a019653","volume":"5","author":"AJ Lepak","year":"2014","unstructured":"Lepak, A. J. & Andes, D. R. Antifungal pharmacokinetics and pharmacodynamics. Cold Spring Harb. Perspect. Med. 5, a019653 (2014).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"198_CR19","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1128\/AAC.47.4.1179-1186.2003","volume":"47","author":"D Andes","year":"2003","unstructured":"Andes, D. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob. Agents Chemother. 47, 1179\u20131186 (2003).","journal-title":"Antimicrob. Agents Chemother."},{"key":"198_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-51316-z","volume":"14","author":"M Gallorini","year":"2024","unstructured":"Gallorini, M. et al. Immunophenotyping of hemocytes from infected Galleria mellonella larvae as an innovative tool for immune profiling, infection studies and drug screening. Sci. Rep. 14, 759 (2024).","journal-title":"Sci. Rep."},{"key":"198_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00441-017-2653-5","volume":"370","author":"LA Arteaga Blanco","year":"2017","unstructured":"Arteaga Blanco, L. A. et al. Differential cellular immune response of Galleria mellonella to Actinobacillus pleuropneumoniae. Cell Tissue Res. 370, 153\u2013168 (2017).","journal-title":"Cell Tissue Res."},{"key":"198_CR22","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3390\/jof4040128","volume":"4","author":"TC Pereira","year":"2018","unstructured":"Pereira, T. C. et al. Recent advances in the use of Galleria mellonella model to study immune responses against human pathogens. J. Fungi Basel Switz. 4, 128 (2018).","journal-title":"J. Fungi Basel Switz."},{"key":"198_CR23","doi-asserted-by":"publisher","first-page":"ftab013","DOI":"10.1093\/femspd\/ftab013","volume":"79","author":"DFQ Smith","year":"2021","unstructured":"Smith, D. F. Q. & Casadevall, A. Fungal immunity and pathogenesis in mammals versus the invertebrate model organism Galleria mellonella. Pathog. Dis. 79, ftab013 (2021).","journal-title":"Pathog. Dis."},{"key":"198_CR24","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/s42003-022-04340-6","volume":"5","author":"DFQ Smith","year":"2022","unstructured":"Smith, D. F. Q., Dragotakes, Q., Kulkarni, M., Hardwick, J. M. & Casadevall, A. Galleria mellonella immune melanization is fungicidal during infection. Commun. Biol. 5, 1364 (2022).","journal-title":"Commun. Biol."},{"key":"198_CR25","doi-asserted-by":"publisher","first-page":"475","DOI":"10.4161\/viru.1.6.12985","volume":"1","author":"BB Fuchs","year":"2010","unstructured":"Fuchs, B. B., O\u2019Brien, E., Khoury, J. B. E. & Mylonakis, E. Methods for using Galleria mellonella as a model host to study fungal pathogenesis. Virulence 1, 475\u2013482 (2010).","journal-title":"Virulence"},{"key":"198_CR26","doi-asserted-by":"publisher","first-page":"ftaa067","DOI":"10.1093\/femspd\/ftaa067","volume":"78","author":"D Romera","year":"2020","unstructured":"Romera, D. et al. The Galleria mellonella infection model as a system to investigate the virulence of Candida auris strains. Pathog. Dis. 78, ftaa067 (2020).","journal-title":"Pathog. Dis."},{"key":"198_CR27","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3390\/jof4040128","volume":"4","author":"TC Pereira","year":"2018","unstructured":"Pereira, T. C. et al. Recent advances in the use of Galleria mellonella model to study immune responses against human pathogens. J. Fungi 4, 128 (2018).","journal-title":"J. Fungi"},{"key":"198_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1348-0421.2008.00083.x","volume":"53","author":"K Satoh","year":"2009","unstructured":"Satoh, K. et al. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol. Immunol. 53, 41\u201344 (2009).","journal-title":"Microbiol. Immunol."},{"key":"198_CR29","doi-asserted-by":"publisher","first-page":"E246","DOI":"10.1111\/j.1469-0691.2012.03880.x","volume":"18","author":"MC Arendrup","year":"2012","unstructured":"Arendrup, M. C., Cuenca-Estrella, M., Lass-Fl\u00f6rl, C. & Hope, W. EUCAST-AFST. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin. Microbiol. Infect. 18, E246\u2013E247 (2012).","journal-title":"Clin. Microbiol. Infect."},{"key":"198_CR30","unstructured":"Feng, W. & Yang, J. Interpretation of fractional inhibitory concentration index (FICI). Bio-Protoc. Prepr. Repos. https:\/\/bio-protocol.org\/exchange\/preprintdetail?id=2404&type=3 (2023)."},{"key":"198_CR31","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0732-8893(02)00525-4","volume":"45","author":"E Cant\u00f3n","year":"2003","unstructured":"Cant\u00f3n, E. et al. Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species. Diagn. Microbiol. Infect. Dis. 45, 203\u2013206 (2003).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"198_CR32","doi-asserted-by":"publisher","first-page":"303","DOI":"10.4103\/0976-500X.119726","volume":"4","author":"J Charan","year":"2013","unstructured":"Charan, J. & Kantharia, N. D. How to calculate sample size in animal studies? J. Pharmacol. Pharmacother. 4, 303\u2013306 (2013).","journal-title":"J. Pharmacol. Pharmacother."},{"key":"198_CR33","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","volume":"49","author":"NL Dirks","year":"2010","unstructured":"Dirks, N. L. & Meibohm, B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin. Pharmacokinet. 49, 633\u2013659 (2010).","journal-title":"Clin. Pharmacokinet."},{"key":"198_CR34","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/cts.12567","volume":"11","author":"M Ovacik","year":"2018","unstructured":"Ovacik, M. & Lin, K. Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development. Clin. Transl. Sci. 11, 540\u2013552 (2018).","journal-title":"Clin. Transl. Sci."},{"key":"198_CR35","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/jcph.1545","volume":"60","author":"G An","year":"2020","unstructured":"An, G. Concept of pharmacologic target-mediated drug disposition (TMDD) in large-molecule and small-molecule compounds. J. Clin. Pharmacol. 60, 149\u2013163 (2020).","journal-title":"J. Clin. Pharmacol."},{"key":"198_CR36","doi-asserted-by":"publisher","first-page":"151023","DOI":"10.1016\/j.scitotenv.2021.151023","volume":"807","author":"GD Marena","year":"2022","unstructured":"Marena, G. D., Ramos, M. A. D. S., Lima, L. C., Chorilli, M. & Bauab, T. M. Galleria mellonella for systemic assessment of anti-Candida auris using amphotericin B loaded in nanoemulsion. Sci. Total Environ. 807, 151023 (2022).","journal-title":"Sci. Total Environ."},{"key":"198_CR37","doi-asserted-by":"publisher","first-page":"918861","DOI":"10.3389\/fmicb.2022.918861","volume":"13","author":"JM Ruiz Barrionuevo","year":"2022","unstructured":"Ruiz Barrionuevo, J. M. et al. The bacterial and fungal gut microbiota of the greater wax moth, Galleria mellonella L. consuming polyethylene and polystyrene. Front. Microbiol. 13, 918861 (2022).","journal-title":"Front. Microbiol."}],"container-title":["npj Antimicrobials and Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44259-026-00198-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44259-026-00198-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44259-026-00198-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:54:45Z","timestamp":1776257685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44259-026-00198-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["198"],"URL":"https:\/\/doi.org\/10.1038\/s44259-026-00198-4","relation":{},"ISSN":["2731-8745"],"issn-type":[{"value":"2731-8745","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Diatheva S.R.L. supported the study, providing the humanized antibody Dia-T51, but was not involved in carrying out or managing the investigation, nor was it involved in the analysis and interpretation of data and in the preparation of the manuscript. M.M. holds shares in Diatheva S.R.L. V.F. is an employee of Diatheva S.R.L., T.V. and M.M. are inventors of Dia-T51 antibody as declared in patent WO2022096455A1 belonging to Diatheva S.R.L. This does not alter our adherence to the journal policies on sharing data and materials.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}